CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

LUNG CANCER PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review, October 2014

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

The WT1 Gene – Its Role in Tumourigenesis and Prospects for Immunotherapeutic Advances. Lindstedt I1, Lindgren MA1, Andersson E1, Engström W2. In Vivo. 2014 09-10;28(5):675-681.

 

PARP-1 rs3219073 Polymorphism May Contribute to Susceptibility to Lung Cancer.Wang HT1, Gao Y, Zhao YX, et al. Genet Test Mol Biomarkers. 2014 Sep 16. [Epub ahead of print]

 

PARP-1 rs3219073 Polymorphism May Contribute to Susceptibility to Lung Cancer.Wang HT1, Gao Y, Zhao YX, et al. Genet Test Mol Biomarkers. 2014 Sep 16. [Epub ahead of print]

 

DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpression in lung cancer.Yang YC1, Tang YA, Shieh JM, Lin RK, Hsu HS, Wang YC. J Thorac Oncol. 2014 Sep;9(9):1305-15. doi: 10.1097/JTO.0000000000000240.

 

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1.Li G1, Wang X2, Hibshoosh H3, Jin C2, Halmos B2. PLoS One. 2014 Sep 19;9(9):e106349. doi: 10.1371/journal.pone.0106349. eCollection 2014.

 

CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis.

Truesdell P1, Ahn J1, Chander H1, Meens J1, Watt K1, Yang X2, Craig AW1. Oncogene. 2014 Sep 1. doi: 10.1038/onc.2014.280. [Epub ahead of print]

 

Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.Kharbanda A1, Rajabi H1, Jin C1, Tchaicha JH2, Kikuchi E2, Wong KK2, Kufe DW3. Clin Cancer Res. 2014 Sep 4. pii: clincanres.3168.2013. [Epub ahead of print]

SCREENING, DIAGNOSIS AND STAGING

Brain metastases following radical surgical treatment of non-small cell lung cancer: Is preoperative brain imaging important? O’Dowd EL1, Kumaran M2, Anwar S2, Palomo B3, Baldwin DR2. Lung Cancer. 2014 Sep 10. pii: S0169-5002(14)00366-3. doi: 10.1016/j.lungcan.2014.08.021. [Epub ahead of print]

 

The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts.Okayama H1, Schetter AJ1, Ishigame T1, et al. Cancer Epidemiol Biomarkers Prev. 2014 Sep 21. pii: cebp.0182.2014. [Epub ahead of print]

 

Appropriateness of Imaging for Lung Cancer Staging in a National Cohort.Backhus LM1, Farjah F2, Varghese TK2, et al. J Clin Oncol. 2014 Sep 22. pii: JCO.2014.55.6589. [Epub ahead of print]

 

Quality indicators for the evaluation of patients with lung cancer.Mazzone PJ, Vachani A, Chang A, Detterbeck F, Cooke D, Howington J, Dodi A, Arenberg D. Chest. 2014 Sep 1;146(3):659-69. doi: 10.1378/chest.13-2900.

 

Contourlet Textual Features: Improving the Diagnosis of Solitary Pulmonary Nodules in Two Dimensional CT Images.Wang J1, Sun T1, Gao N1, et al. PLoS One. 2014 Sep 24;9(9):e108465. doi: 10.1371/journal.pone.0108465. eCollection 2014.

 

The Role of Immunohistochemical Analysis in the Evaluation of EML4-ALK Gene Rearrangement in Lung Cancer.Sullivan HC1, Fisher KE, Hoffa AL, Wang J, Saxe D, Siddiqui MT, Cohen C. Appl Immunohistochem Mol Morphol. 2014 Sep 26. [Epub ahead of print]

 

Outcome of patients with negative and unsatisfactory cytologic specimens obtained by endobronchial ultrasound-guided transbronchial fine-needle aspiration of mediastinal lymph nodes. Mehta HJ1, Tanner NT, Silvestri G, et al. Cancer Cytopathol. 2014 Sep 3. doi: 10.1002/cncy.21482. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – SURGERY

Benefit of Adjuvant Chemotherapy After Resection of Stage II (T1-2N1M0) Non-Small Cell Lung Cancer in Elderly Patients.Berry MF1, Coleman BK, Curtis LH, Worni M, D’Amico TA, Akushevich I. Ann Surg Oncol. 2014 Sep 6. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – CHEMOTHERAPY

Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib.Suleiman AA1, Frechen S, Scheffler M, et al. J Thorac Oncol. 2014 Sep 12. [Epub ahead of print]

 

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.Yang JJ, Huang C, Chen GY, Song Y, Cheng Y, Yan HH, Zhou Q, Wu YL1. BMC Cancer. 2014 Sep 20;14:684. doi: 10.1186/1471-2407-14-684.

 

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Kodama T1, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H. Cancer Chemother Pharmacol. 2014 Sep 10. [Epub ahead of print]

 

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.Soria JC1, DeBraud F2, Bahleda R3, et al. Ann Oncol. 2014 Sep 5. pii: mdu390. [Epub ahead of print]

 

Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial.Heigener DF1, Pereira JR, Felip E, et al. Target Oncol. 2014 Sep 9. [Epub ahead of print]

 

Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study.Fennell DA1, Myrand SP2, Nguyen TS2, et al. PLoS One. 2014 Sep 24;9(9):e107455. doi: 10.1371/journal.pone.0107455. eCollection 2014.

 

Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC.Brodie SA1, Lombardo C2, Li G2, et al. PLoS One. 2014 Sep 15;9(9):e107124. doi: 10.1371/journal.pone.0107124. eCollection 2014.

 

Phase II Study of Docetaxel-plus-Bevacizumab Combination Therapy in Patients Previously Treated for Advanced Non-squamous Non-small Cell Lung Cancer.Ohyanagi F1, Yanagitani N1, Kudo K1, et al. Anticancer Res. 2014 Sep;34(9):5153-8.

 

Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.

Sekine A1, Satoh H, Iwasawa T, et al. Med Oncol. 2014 Oct;31(10):228. doi: 10.1007/s12032-014-0228-9. Epub 2014 Sep 11.

 

Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer.Kimura H1, Matsui Y, Ishikawa A, Nakajima T, Yoshino M, Sakairi Y. Cancer Immunol Immunother. 2014 Sep 28. [Epub ahead of print]

 

Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.Shaw AT1, Ou SH, Bang YJ, et al. N Engl J Med. 2014 Sep 27. [Epub ahead of print]

 

Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.Sonobe M1, Okubo KI, Teramukai S, et al. Cancer Chemother Pharmacol. 2014 Sep 25. [Epub ahead of print]

 

Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib.Schuler M1, Fischer JR2, Grohé C2, et al. Oncologist. 2014 Sep 17. pii: theoncologist.2014-0103. [Epub ahead of print]

 

Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. Zhao H1, Zhang H, Du Y, Gu X. Tumour Biol. 2014 Sep 17. [Epub ahead of print]

 

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib.Katayama R1, Friboulet L2, Koike S3, et al. Clin Cancer Res. 2014 Sep 16. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – RADIOTHERAPY

Frequency filtering based analysis on the cardiac induced lung tumor motion and its impact on the radiotherapy management.Chen T1, Qin S2, Xu X2, Jabbour SK3, Haffty BG3, Yue NJ3. Radiother Oncol. 2014 Sep 15. pii: S0167-8140(14)00328-4. doi: 10.1016/j.radonc.2014.08.007. [Epub ahead of print]

 

Predictors and management of chest wall toxicity after lung stereotactic body radiotherapy.Shaikh T1, Turaka A2. Cancer Treat Rev. 2014 Sep 16. pii: S0305-7372(14)00150-9. doi: 10.1016/j.ctrv.2014.09.003. [Epub ahead of print]

 

Lung Stereotactic Body Radiation Therapy: Regional Nodal Failure Is Not Predicted by Tumor Size.Marwaha G1, Stephans KL, Woody NM, Reddy CA, Videtic GM. Thorac Oncol. 2014 Sep 2. [Epub ahead of print]

 

Phase 2 Study of Concurrent Cetuximab Plus Definitive Thoracic Radiation Therapy Followed by Consolidation Docetaxel Plus Cetuximab in Poor Prognosis or Elderly Patients With Locally Advanced Non-Small Cell Lung Cancer.Dilling TJ1, Extermann M2, Kim J3, et al. Int J Radiat Oncol Biol Phys. 2014 Sep 9. pii: S0360-3016(14)03530-5. doi: 10.1016/j.ijrobp.2014.07.023. [Epub ahead of print]

 

Comparative Effectiveness of Intensity-Modulated Versus 3D Conformal Radiation Therapy Among Medicare Patients with Stage III Lung Cancer.Chen AB1, Li L, Cronin A, Schrag D. J Thorac Oncol. 2014 Sep 12. [Epub ahead of print]

 

Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-Small Cell Lung Cancer.Fried DV1, Tucker SL2, Zhou S3, Liao Z4, Mawlawi O5, Ibbott G1, Court LE6. Int J Radiat Oncol Biol Phys. 2014 Sep 11. pii: S0360-3016(14)03499-3. doi: 10.1016/j.ijrobp.2014.07.020. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – OTHER

Predictors of Early Recurrence for Node-Negative T1 to T2b Non-Small Cell Lung Cancer. Kiankhooy A1, Taylor MD1, LaPar DJ1, et al. Ann Thorac Surg. 2014 Aug 15. pii: S0003-4975(14)01181-3. doi: 10.1016/j.athoracsur.2014.05.061. [Epub ahead of print]

 

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non-Small Cell Lung Cancer.Lou F1, Sima CS2, Rusch VW3, Jones DR3, Huang J4. Ann Thorac Surg. 2014 Aug 7. pii: S0003-4975(14)01268-5. doi: 10.1016/j.athoracsur.2014.05.070. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – SMALL CELL LUNG CANCER (SCLC)

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.Slotman BJ1, van Tinteren H2, Praag JO3, Knegjens JL4, El Sharouni SY5, Hatton M6, Keijser A7, Faivre-Finn C8, Senan S9. Lancet. 2014 Sep 14. pii: S0140-6736(14)61085-0. doi:

 

Risk factors for brain metastases in completely resected small cell lung cancer: a retrospective study to identify patients most likely to benefit from prophylactic cranial irradiation.Zhu H, Bi Y, Han A, Luo J, Li M, Shi F, Kong L1, Yu J. Radiat Oncol. 2014 Sep 20;9:216. doi: 10.1186/1748-717X-9-216.

 

Advances in pharmacotherapy of small cell lung cancer.Kalemkerian GP. Expert Opin Pharmacother. 2014 Sep 26:1-12. [Epub ahead of print]

 

Ganitumab for the treatment of small-cell lung cancer.Martínez P1, Sales Fidalgo PA, Felip E. Expert Opin Investig Drugs. 2014 Oct;23(10):1423-32. doi: 10.1517/13543784.2014.951434. Epub 2014 Sep 5.

 

Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer.Wildey G1, Chen Y1, Lent I1, Stetson L1, Pink J1, Barnholtz-Sloan JS1, Dowlati A2. PLoS One. 2014 Sep 8;9(9):e106784. doi: 10.1371/journal.pone.0106784. eCollection 2014.

 

Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens.Leong TL1, Marini KD1, Rossello FJ2, et al. PLoS One. 2014 Sep 5;9(9):e106862. doi: 10.1371/journal.pone.0106862. eCollection 2014.

 

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.Loriot Y1, Mordant P1, Dugue D2, et al. Cell Death Dis. 2014 Sep 18;5:e1423. doi: 10.1038/cddis.2014.365.

 

A study of elderly patients with limited-stage small-cell lung cancer after combined chemoradiotherapy.Su J1, Zhu S, Liu Z, Li J, Shen W, Li R. Am J Ther. 2014 Sep-Oct;21(5):371-6. doi: 10.1097/MJT.0b013e3182541cb3.

 

Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.Umemura S1, Mimaki S, Makinoshima H, et al. J Thorac Oncol. 2014 Sep;9(9):1324-31. doi: 10.1097/JTO.0000000000000250.

 

RET mutation and expression in small-cell lung cancer.Dabir S1, Babakoohi S, Kluge A, et al. J Thorac Oncol. 2014 Sep;9(9):1316-23. doi: 10.1097/JTO.0000000000000234.

PALLIATIVE AND SUPPORTIVE CARE

Inhaled medicinal cannabis and the immunocompromised patient.Ruchlemer R1, Amit-Kohn M, Raveh D, Hanuš L. Support Care Cancer. 2014 Sep 13. [Epub ahead of print]

 

Symptom Expression in the Last Seven Days of Life Among Cancer Patients Admitted to Acute Palliative Care Units.Hui D1, Santos RD2, Chisholm GB3, Bruera E4. J Pain Symptom Manage. 2014 Sep 18. pii: S0885-3924(14)00466-7. doi: 10.1016/j.jpainsymman.2014.09.003. [Epub ahead of print]

 

An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients.Gralla RJ1, Hollen PJ, Msaouel P, Davis BV, Petersen J. J Thorac Oncol. 2014 Sep;9(9):1243-8. doi: 10.1097/JTO.0000000000000244.

 

Age disparity in palliative radiation therapy among patients with advanced cancer.Wong J1, Xu B2, Yeung HN3, et al. Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):224-30. doi: 10.1016/j.ijrobp.2014.03.050.

 

A tailored Web-based psychoeducational intervention for cancer patients and their family caregivers.Northouse L1, Schafenacker A, Barr KL, et al. Cancer Nurs. 2014 Sep-Oct;37(5):321-30. doi: 10.1097/NCC.0000000000000159.

 

Exploring hope and healing in patients living with advanced non-small cell lung cancer.Eustache C1, Jibb E1, Grossman M2. Oncol Nurs Forum. 2014 Sep 1;41(5):497-508. doi: 10.1188/14.ONF.497-508.

 

Occupational therapy use by older adults with cancer.Pergolotti M1, Cutchin MP2, Weinberger M3, Meyer AM4. Am J Occup Ther. 2014 Sep-Oct;68(5):597-607. doi: 10.5014/ajot.2014.011791.

 

Evidence of associations between cytokine gene polymorphisms and quality of life in patients with cancer and their family caregivers.Alexander K1, Cooper B2, Paul SM2, et al. Oncol Nurs Forum. 2014 Sep 1;41(5):E267-81. doi: 10.1188/14.ONF.E267-E281.

 

A differential item function analysis of somatic symptoms of depression in people with cancer.

Jones SM1, Ludman EJ2, McCorkle R2, Reid R2, Bowles EJ2, Penfold R2, Wagner EH2. J Affect Disord. 2014 Sep 10;170C:131-137. doi: 10.1016/j.jad.2014.09.002. [Epub ahead of print]

 

Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial.Badr H1, Smith CB, Goldstein NE, Gomez JE, Redd WH. Cancer. 2014 Sep 10. doi: 10.1002/cncr.29009. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

Identification of Green Tea Catechins as Potent Inhibitors of the Polo-Box Domain of Polo-Like kinase 1.Shan HM1, Shi Y, Quan J. ChemMedChem. 2014 Sep 5. doi: 10.1002/cmdc.201402284. [Epub ahead of print]

Annona squamosa Linn: Cytotoxic activity found in leaf extract against human tumor cell lines. Wang DS1, Rizwani GH2, Guo H3, et al. Pak J Pharm Sci. 2014 Sep;27(5 Spec No):1559-63.

MISCELLANEOUS WORKS

Opportunities to address lung cancer disparities among African Americans.Coughlin SS1, Matthews-Juarez P, Juarez PD, Melton CE, King M. Cancer Med. 2014 Sep 14. doi: 10.1002/cam4.348. [Epub ahead of print]

Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer. Kehl KL1, Arora NK1, Schrag D1, Ayanian JZ1, Clauser SB1, Klabunde CN1, Kahn KL1, Fletcher RH1, Keating NL2. J Natl Cancer Inst. 2014 Sep 13;106(10). pii: dju216. doi: 10.1093/jnci/dju216. Print 2014 Oct.

Role of Nicotine Dependence on the Relationship between Variants in the Nicotinic Receptor Genes and Risk of Lung Adenocarcinoma.Tseng TS1, Park JY2, Zabaleta J3, et al. PLoS One. 2014 Sep 18;9(9):e107268. doi: 10.1371/journal.pone.0107268. eCollection 2014.

Racial disparities in cancer care in the Veterans Affairs health care system and the role of site of care.Samuel CA1, Landrum MB, McNeil BJ, Bozeman SR, Williams CD, Keating NL. Am J Public Health. 2014 Sep;104 Suppl 4:S562-71. doi: 10.2105/AJPH.2014.302079.

Is previous respiratory disease a risk factor for lung cancer?Denholm R1, Schüz J, Straif K, et al. Am J Respir Crit Care Med. 2014 Sep 1;190(5):549-59. doi: 10.1164/rccm.201402-0338OC.

Impact of lung cancer clinical nurse specialists on emergency admissions.Leary A1, Baxter J. Br J Nurs. 2014 Sep 25;23(17):935-8. doi: 10.12968/bjon.2014.23.17.935.

US lung cancer trends by histologic type. Lewis DR1, Check DP, Caporaso NE, Travis WD, Devesa SS. Cancer. 2014 Sep 15;120(18):2883-92. doi: 10.1002/cncr.28749. Epub 2014 Aug 11.

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)